
zzso zzso zzso zzso zzso is a highly zzso zzso zzso which possesses potent in zzso and in zzso zzso zzso Previous phase I studies had been conducted using a single zzso every 28 zzso 

We conducted a phase I study of zzso zzso on a daily zzso every 28 days zzso Thirty patients received 68 cycles of therapy at 5 dose levels zzso zzso 

zzso zzso and zzso were the zzso zzso Other zzso zzso included zzso and zzso zzso fatigue and transient zzso of serum zzso and zzso zzso No cardiac toxicity was zzso There were no partial or complete zzso zzso 

The recommended phase II dose using the schedule defined in this study is 500 zzso 

